Bilateral Acute Depigmentation of Iris (BADI) Post COVID Infection following Systemic Moxifloxacin Therapy.

Pas encore traduit Pas encore traduit
Auteurs
Catégorie Primary study
JournalOcular immunology and inflammation
Year 2022
PURPOSE: To report a case of BADI post Covid infection following systemic moxifloxacin therapy. METHODS: Observational case study. CASE REPORT: A 28-year-old female presented to us with complaints of redness and pain in the right eye since 5 days. History revealed use of systemic moxifloxacin for covid infection. She was managed with topical corticosteroids and cycloplegics following a diagnosis of BADI. CONCLUSION: Bilateral acute depigmentation of iris (BADI) is a rare disease entity associated with the release of iris pigments. Various underlying aetiologies have been associated with the same. Although BADI is a benign, self-limiting disorder, it needs to be differentiated with other potential severe clinical entities. SARS-CoV2 has been associated with various ocular manifestations. However, to the best of our knowledge, BADI has never been associated with COVID infection yet. We report a case of BADI in a young healthy Asian middle - aged female 3 months after an acute COVID infection.
Epistemonikos ID: 72cda48c5caa7fb91a7355e099515034b054dc58
First added on: Apr 30, 2022